Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 12/20 | 0.39 |
| ▸ | CD44 | P16070 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.35 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.35 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.35 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31111348 | 1.00 | PNMT (0.43) | PNMTSSTR4CD44DRD2DRD3 | |
| SCHEMBL3188143 | 0.78 | PARP1 (0.47) | PNMTDRD2 | |
| SCHEMBL20565032 | 0.76 | RIPK1 (0.42) | — | |
| SCHEMBL21800420 | 0.75 | PNMT (0.44) | PNMT | |
| SCHEMBL21867302 | 0.75 | NOTUM (0.36) | PNMTSSTR4DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL20564467 | 0.75 | RIPK1 (0.41) | — | |
| Hydrochloric Acid SCHEMBL20565224 | 0.75 | RIPK1 (0.41) | — | |
| SCHEMBL4695076 | 0.75 | PARP1 (0.38) | PNMT | |
| SCHEMBL22513280 | 0.75 | SSTR4 (0.46) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL20565286 | 0.75 | SSTR4 (0.47) | SSTR4SSTR1SSTR2SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2025-01-09 | — | — | US | disclosed |
| US-12129263-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3624797-A1 | KINASE INHIBITORS AND USES THEREOF | Denali Therapeutics Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2018213632-A1 | KINASE INHIBITORS AND USES THEREOF | DENALI THERAPEUTICS INC. (US) | 2018-11-22 | — | — | WO | disclosed |
| WO-2009080725-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | PNMT 3082/4885SSTR4 4099/4885CD44 3586/4885 |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | PNMT 3082/4885SSTR4 4099/4885CD44 3586/4885 |
| US-11203600-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | PNMT 3082/4885SSTR4 4099/4885CD44 3586/4885 |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | PNMT 3082/4885SSTR4 4099/4885CD44 3586/4885 |
| US-12129263-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | PNMT 3082/4885SSTR4 4099/4885CD44 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.